2022年12月8日

ObvioHealth是該地區首批進行全虛擬研究的分散臨床試驗參與者之一。ObvioHealth正與甲骨文公司(Oracle)在亞太地區展開合作，通過更有效地整合不同的數據集，更快地將突破性療法推向市場。該聯盟將能夠快速收集、整合和分析從站點、患者、設備和實驗室收集的多源數據。ObvioHealth首席執行官Ivan Jarry說:“由於dct的設計目的是為了讓患者更方便，因此它們自然涉及更複雜的數據來源——物理站點、電子健康記錄、可穿戴設備和移動應用程序——而甲骨文的技術為我們提供了一個統一的環境，將所有這些數據集中在一個地方。”“與甲骨文的合作將使我們能夠集成更複雜、更多樣化的數據集。”在此之前，obvihealth發布了下一代去中心化臨床試驗(DCT)平台和移動應用程序ObvioGo。該平台的eConsent、eCOA和ePRO功能將完全集成到Oracle clinical One雲服務(clinical One)中，促進藥物級分析和報告，從而提供更及時的患者見解。讚助商受益於ObvioGo平台的設備集成以及Oracle Clinical One強大的數據管理功能。熟悉Oracle係統的站點可以在現有的工作流程中集成分散的試驗組件。甲骨文健康科學高級副總裁兼總經理Henry McNamara表示:“獲取數據是將療法從臨床試驗轉移到可用療法的基石，亞太地區的試驗發起人越來越多地尋求更分散的模型，以提高試驗的公平性、可獲得性和數據可用性。”“ObvioHealth在這個市場進行DCT試驗方麵擁有寶貴的行業經驗。 By integrating ObvioHealth’s experience with our centralized capabilities, we’re helping reduce costs, accelerate timelines, and increase the depth of data insights for trials in the region.” An Oracle provider in Asia Pacific, ObvioHealth is one of the first DCT players to conduct fully virtual studies in the region. In addition to its New York headquarters, the company has offices in Singapore, Australia, and Europe. The VRO is also partnered with Novotech, an Asia-Pacific biotech specialist contract research organization. ObvioHealth is an end-to-end virtual research organization (VRO) that delivers better data to sponsors and an easier clinical trial experience for participants. The company developed and launched one of the first patient-centric apps downloadable on smartphones, enabling people to participate in clinical trials from their homes. In the five years since that launch, the company has been awarded 46 studies from 28 blue chip clients, implemented in 28 countries, across 18 different therapeutic areas.